LT2643352T - Antigeną onkostatiną m (osm) surišantys baltymai - Google Patents

Antigeną onkostatiną m (osm) surišantys baltymai

Info

Publication number: LT2643352T
Authority: LT; Lithuania
Prior art keywords: oncostatin; osm; antigen binding; binding proteins; proteins
Prior art date: 2010-11-23

Application number

LTEP11785424.0T

Other languages

English (en)

Inventor

Gary Peter Bembridge

Chun-Wa Chung

Maria Feeney

Susannah Karen Ford

Ian Kirby

Ruth Mcadam

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-23

Filing date

2011-11-21

Publication date

2018-08-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45001764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2643352(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-11-21 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2018-08-10 Publication of LT2643352T publication Critical patent/LT2643352T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Investigating Or Analysing Biological Materials (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Measuring Volume Flow (AREA)

LTEP11785424.0T 2010-11-23 2011-11-21 Antigeną onkostatiną m (osm) surišantys baltymai LT2643352T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41649510P	2010-11-23	2010-11-23
PCT/EP2011/070604 WO2012069433A2 (en)	2010-11-23	2011-11-21	Antigen binding proteins

Publications (1)

Publication Number	Publication Date
LT2643352T true LT2643352T (lt)	2018-08-10

Family

ID=45001764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP11785424.0T LT2643352T (lt)	2010-11-23	2011-11-21	Antigeną onkostatiną m (osm) surišantys baltymai

Country Status (40)

Country	Link
US (4)	US8916695B2 (lt)
EP (3)	EP3369744A1 (lt)
JP (2)	JP6351973B2 (lt)
KR (2)	KR101947356B1 (lt)
CN (1)	CN103328508B (lt)
AR (1)	AR083937A1 (lt)
AU (1)	AU2011333878B2 (lt)
BR (1)	BR112013012627A2 (lt)
CA (1)	CA2818534A1 (lt)
CL (1)	CL2013001466A1 (lt)
CO (1)	CO6801627A2 (lt)
CY (1)	CY1120448T1 (lt)
DK (1)	DK2643352T3 (lt)
DO (1)	DOP2013000113A (lt)
EA (1)	EA027256B1 (lt)
ES (1)	ES2681949T3 (lt)
HR (1)	HRP20181092T1 (lt)
HU (1)	HUE039412T2 (lt)
IL (1)	IL226157B (lt)
JO (1)	JO3455B1 (lt)
LT (1)	LT2643352T (lt)
MA (1)	MA34742B1 (lt)
ME (1)	ME03069B (lt)
MX (1)	MX351887B (lt)
MY (1)	MY170404A (lt)
NZ (1)	NZ610464A (lt)
PE (1)	PE20140519A1 (lt)
PH (1)	PH12013501036B1 (lt)
PL (1)	PL2643352T3 (lt)
PT (1)	PT2643352T (lt)
RS (1)	RS57502B1 (lt)
SG (2)	SG190232A1 (lt)
SI (1)	SI2643352T1 (lt)
SM (1)	SMT201800397T1 (lt)
TR (1)	TR201810773T4 (lt)
TW (1)	TWI504609B (lt)
UA (1)	UA111954C2 (lt)
UY (1)	UY33743A (lt)
WO (1)	WO2012069433A2 (lt)
ZA (1)	ZA201303541B (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112013009083B1 (pt)	2010-10-13	2021-08-10	Janssen Biotech, Inc.	Anticorpos humanos para oncostatina m, seu processo de fabricação, fragmento de ligação a antígeno, composição farmacêutica, polinucleotídeo isolado, célula hospedeira recombinante estavelmente transformada ou transfectada
LT2643352T (lt)	2010-11-23	2018-08-10	Glaxo Group Limited	Antigeną onkostatiną m (osm) surišantys baltymai
US9550828B2 (en)	2013-09-05	2017-01-24	Boise State University	Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US20170327573A1 (en)	2014-09-24	2017-11-16	Universitá Degli Studi Di Padova	Composition to induce bone marrow stem cell mobilization
CN107530431B (zh) *	2015-01-29	2022-01-07	牛津大学创新有限公司	生物标志物
GB201614627D0 (en) *	2016-08-30	2016-10-12	Glaxosmithkline Ip Dev Ltd	Antigen binding proteins
FR3090637A1 (fr) *	2018-12-21	2020-06-26	Universite De Poitiers	Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations.
US11633457B2 (en)	2019-04-11	2023-04-25	Boise State University	Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use
TWI904261B (zh)	2020-10-19	2025-11-11	美商碩騰服務公司	犬及貓抑瘤素Ｍ受體β之抗體及其用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57106673A (en)	1980-12-24	1982-07-02	Chugai Pharmaceut Co Ltd	Dibenzo(b,f)(1,4)oxazepin derivative
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4666884A (en)	1984-04-10	1987-05-19	New England Deaconess Hospital	Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US4873316A (en)	1987-06-23	1989-10-10	Biogen, Inc.	Isolation of exogenous recombinant proteins from the milk of transgenic mammals
AU654811B2 (en)	1990-03-20	1994-11-24	Trustees Of Columbia University In The City Of New York, The	Chimeric antibodies with receptor binding ligands in place of their constant region
EP0640094A1 (en)	1992-04-24	1995-03-01	The Board Of Regents, The University Of Texas System	Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5783672A (en)	1994-05-26	1998-07-21	Immunex Corporation	Receptor for oncostatin M
GB9424449D0 (en)	1994-12-02	1995-01-18	Wellcome Found	Antibodies
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US5747035A (en)	1995-04-14	1998-05-05	Genentech, Inc.	Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997043316A1 (en)	1996-05-10	1997-11-20	Beth Israel Deaconess Medical Center, Inc.	Physiologically active molecules with extended half-lives and methods of using same
DE19742706B4 (de)	1997-09-26	2013-07-25	Pieris Proteolab Ag	Lipocalinmuteine
US5958442A (en) *	1997-10-24	1999-09-28	Bristol-Myers Squibb Company	Oncostatin M for treating inflammation
EP1060194A1 (en)	1998-02-25	2000-12-20	Lexigen Pharmaceuticals Corp.	Enhancing the circulating half-life of antibody-based fusion proteins
GB9806530D0 (en) *	1998-03-26	1998-05-27	Glaxo Group Ltd	Inflammatory mediator
GB9809839D0 (en)	1998-05-09	1998-07-08	Glaxo Group Ltd	Antibody
WO2000009560A2 (en)	1998-08-17	2000-02-24	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
IL127127A0 (en)	1998-11-18	1999-09-22	Peptor Ltd	Small functional units of antibody heavy chain variable regions
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en)	1998-12-10	2006-10-03	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
MX353234B (es)	1999-01-15	2018-01-08	Genentech Inc	Variantes de polipeptidos con función efectora alterada.
DK1176195T3 (da)	1999-04-09	2013-06-24	Kyowa Hakko Kirin Co Ltd	Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
WO2001029246A1 (fr)	1999-10-19	2001-04-26	Kyowa Hakko Kogyo Co., Ltd.	Procede de production d'un polypeptide
ATE382636T1 (de) *	2000-04-21	2008-01-15	Conaris Res Inst Ag	Fusionsproteine, die zwei lösliche gp130 moleküle enthalten
EP1332209B1 (en)	2000-09-08	2009-11-11	Universität Zürich	Collections of repeat proteins comprising repeat modules
US6374470B1 (en)	2000-10-06	2002-04-23	Milliken & Company	Face plate for spun-like textured yarn
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DE60143544D1 (de)	2000-12-12	2011-01-05	Medimmune Llc	Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
WO2004006955A1 (en) *	2001-07-12	2004-01-22	Jefferson Foote	Super humanized antibodies
WO2003011878A2 (en)	2001-08-03	2003-02-13	Glycart Biotechnology Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP2281837B1 (en)	2001-08-10	2016-10-05	Aberdeen University	Antigen binding domains from fish
ES2319426T3 (es)	2003-07-04	2009-05-07	Affibody Ab	Polipeptidos que presentan afinidad de union por her-2.
AU2003275958A1 (en)	2003-08-25	2005-03-10	Pieris Proteolab Ag	Muteins of tear lipocalin
PE20090046A1 (es) *	2003-11-10	2009-01-26	Schering Corp	Anticuerpo recombinante humanizado anti-interleuquina 10
AU2004296376B2 (en)	2003-12-05	2010-03-04	Bristol-Myers Squibb Company	Inhibitors of type 2 vascular endothelial growth factor receptors
ATE515515T1 (de) *	2004-03-30	2011-07-15	Glaxo Group Ltd	Immunglobuline gegen menschlisches osm
GB0407197D0 (en) *	2004-03-30	2004-05-05	Glaxo Group Ltd	Immunoglobulins
WO2006014679A1 (en)	2004-07-21	2006-02-09	Glycofi, Inc.	Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
EP1921090B1 (en)	2005-07-22	2015-01-14	Kyowa Hakko Kirin Co., Ltd.	Genetically modified antibody composition
US7923538B2 (en)	2005-07-22	2011-04-12	Kyowa Hakko Kirin Co., Ltd	Recombinant antibody composition
BRPI0711908B8 (pt) *	2006-05-25	2021-05-25	Glaxo Group Ltd	anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo.
EP1958957A1 (en)	2007-02-16	2008-08-20	NascaCell Technologies AG	Polypeptide comprising a knottin protein moiety
WO2010056893A1 (en) *	2008-11-13	2010-05-20	Imclone Llc	Humanization and affinity-optimization of antibodies
BR112013009083B1 (pt) *	2010-10-13	2021-08-10	Janssen Biotech, Inc.	Anticorpos humanos para oncostatina m, seu processo de fabricação, fragmento de ligação a antígeno, composição farmacêutica, polinucleotídeo isolado, célula hospedeira recombinante estavelmente transformada ou transfectada
LT2643352T (lt)	2010-11-23	2018-08-10	Glaxo Group Limited	Antigeną onkostatiną m (osm) surišantys baltymai

2011
- 2011-11-21 LT LTEP11785424.0T patent/LT2643352T/lt unknown
- 2011-11-21 DK DK11785424.0T patent/DK2643352T3/en active
- 2011-11-21 SM SM20180397T patent/SMT201800397T1/it unknown
- 2011-11-21 SG SG2013035951A patent/SG190232A1/en unknown
- 2011-11-21 AR ARP110104328A patent/AR083937A1/es unknown
- 2011-11-21 BR BR112013012627A patent/BR112013012627A2/pt not_active Application Discontinuation
- 2011-11-21 UY UY0001033743A patent/UY33743A/es not_active Application Discontinuation
- 2011-11-21 EP EP18163940.2A patent/EP3369744A1/en not_active Withdrawn
- 2011-11-21 CA CA2818534A patent/CA2818534A1/en not_active Abandoned
- 2011-11-21 JP JP2013539295A patent/JP6351973B2/ja not_active Expired - Fee Related
- 2011-11-21 HR HRP20181092TT patent/HRP20181092T1/hr unknown
- 2011-11-21 UA UAA201305873A patent/UA111954C2/uk unknown
- 2011-11-21 KR KR1020187027871A patent/KR101947356B1/ko not_active Expired - Fee Related
- 2011-11-21 ME MEP-2018-182A patent/ME03069B/me unknown
- 2011-11-21 NZ NZ610464A patent/NZ610464A/en not_active IP Right Cessation
- 2011-11-21 SG SG10201500388PA patent/SG10201500388PA/en unknown
- 2011-11-21 RS RS20180819A patent/RS57502B1/sr unknown
- 2011-11-21 WO PCT/EP2011/070604 patent/WO2012069433A2/en not_active Ceased
- 2011-11-21 CN CN201180065512.0A patent/CN103328508B/zh not_active Expired - Fee Related
- 2011-11-21 TW TW100142577A patent/TWI504609B/zh not_active IP Right Cessation
- 2011-11-21 PH PH1/2013/501036A patent/PH12013501036B1/en unknown
- 2011-11-21 AU AU2011333878A patent/AU2011333878B2/en not_active Ceased
- 2011-11-21 MY MYPI2013700832A patent/MY170404A/en unknown
- 2011-11-21 EA EA201390537A patent/EA027256B1/ru not_active IP Right Cessation
- 2011-11-21 PL PL11785424T patent/PL2643352T3/pl unknown
- 2011-11-21 EP EP17166131.7A patent/EP3211009A1/en not_active Withdrawn
- 2011-11-21 HU HUE11785424A patent/HUE039412T2/hu unknown
- 2011-11-21 SI SI201131537T patent/SI2643352T1/sl unknown
- 2011-11-21 EP EP11785424.0A patent/EP2643352B1/en active Active
- 2011-11-21 US US13/989,191 patent/US8916695B2/en active Active
- 2011-11-21 ES ES11785424.0T patent/ES2681949T3/es active Active
- 2011-11-21 PT PT117854240T patent/PT2643352T/pt unknown
- 2011-11-21 TR TR2018/10773T patent/TR201810773T4/tr unknown
- 2011-11-21 KR KR1020137016213A patent/KR20130119948A/ko not_active Ceased
- 2011-11-21 PE PE2013001238A patent/PE20140519A1/es active IP Right Grant
- 2011-11-21 MX MX2013005843A patent/MX351887B/es active IP Right Grant
- 2011-11-21 JO JOP/2011/0353A patent/JO3455B1/ar active
2013
- 2013-05-05 IL IL226157A patent/IL226157B/en active IP Right Grant
- 2013-05-15 ZA ZA2013/03541A patent/ZA201303541B/en unknown
- 2013-05-17 CO CO13122422A patent/CO6801627A2/es unknown
- 2013-05-21 DO DO2013000113A patent/DOP2013000113A/es unknown
- 2013-05-23 CL CL2013001466A patent/CL2013001466A1/es unknown
- 2013-06-19 MA MA36018A patent/MA34742B1/fr unknown
2014
- 2014-11-13 US US14/540,247 patent/US9605063B2/en not_active Expired - Fee Related
2016
- 2016-11-11 JP JP2016220093A patent/JP2017078072A/ja active Pending
2017
- 2017-02-09 US US15/428,528 patent/US10808029B2/en not_active Expired - Fee Related
2018
- 2018-07-24 CY CY20181100770T patent/CY1120448T1/el unknown
2020
- 2020-07-09 US US16/924,628 patent/US20210017270A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DOP2013000113A (es)	2013-12-15
EA201390537A1 (ru)	2014-01-30
HUE039412T2 (hu)	2018-12-28
US20130251724A1 (en)	2013-09-26
EP3369744A1 (en)	2018-09-05
CO6801627A2 (es)	2013-11-29
CN103328508A (zh)	2013-09-25
HRP20181092T1 (hr)	2018-09-21
UY33743A (es)	2012-06-29
BR112013012627A2 (pt)	2016-10-04
SI2643352T1 (sl)	2018-12-31
AR083937A1 (es)	2013-04-10
ZA201303541B (en)	2014-11-26
EP3211009A1 (en)	2017-08-30
EP2643352A2 (en)	2013-10-02
TR201810773T4 (tr)	2018-08-27
AU2011333878A1 (en)	2013-05-09
JP2014507373A (ja)	2014-03-27
PL2643352T3 (pl)	2018-10-31
PH12013501036B1 (en)	2019-05-10
US9605063B2 (en)	2017-03-28
RS57502B1 (sr)	2018-10-31
SG10201500388PA (en)	2015-03-30
MX2013005843A (es)	2013-07-05
IL226157B (en)	2020-10-29
MY170404A (en)	2019-07-27
DK2643352T3 (en)	2018-07-30
IL226157A0 (en)	2013-06-27
MX351887B (es)	2017-11-01
ME03069B (me)	2019-01-20
CL2013001466A1 (es)	2014-06-27
EA027256B1 (ru)	2017-07-31
CA2818534A1 (en)	2012-05-31
TW201235358A (en)	2012-09-01
CN103328508B (zh)	2015-12-16
UA111954C2 (uk)	2016-07-11
JP6351973B2 (ja)	2018-07-04
PH12013501036A1 (en)	2013-07-15
US20150064201A1 (en)	2015-03-05
CY1120448T1 (el)	2019-07-10
PE20140519A1 (es)	2014-04-30
US10808029B2 (en)	2020-10-20
NZ610464A (en)	2015-02-27
AU2011333878B2 (en)	2016-01-14
EP2643352B1 (en)	2018-05-02
SG190232A1 (en)	2013-06-28
KR20130119948A (ko)	2013-11-01
ES2681949T3 (es)	2018-09-17
SMT201800397T1 (it)	2018-09-13
MA34742B1 (fr)	2013-12-03
TWI504609B (zh)	2015-10-21
US20170152312A1 (en)	2017-06-01
WO2012069433A2 (en)	2012-05-31
WO2012069433A3 (en)	2012-08-09
US20210017270A1 (en)	2021-01-21
KR101947356B1 (ko)	2019-02-12
PT2643352T (pt)	2018-08-01
JO3455B1 (ar)	2020-07-05
JP2017078072A (ja)	2017-04-27
US8916695B2 (en)	2014-12-23
KR20180110199A (ko)	2018-10-08

Publication	Publication Date	Title
HUS1900048I1 (hu)	2019-11-28	Anti-IL-23 antitestek
SG10201401681PA (en)	2014-07-30	Novel antigen binding proteins
ZA201402258B (en)	2021-05-26	Cd27l antigen binding proteins
ZA201208906B (en)	2014-05-28	Humanised antigen binding proteins to myostatin6
ZA201303541B (en)	2014-11-26	Antigen binding proteins to oncostatin m (osm)
EP2681239B8 (en)	2015-09-09	Antigen binding proteins
ZA201108536B (en)	2012-09-26	Bispecific antigen binding proteins
ZA201205624B (en)	2014-01-29	Cd127 binding proteins
GB201000467D0 (en)	2010-02-24	Antibodies
EP2569012A4 (en)	2013-10-30	ANTI-FGFR2 ANTIBODY
IL229618A0 (en)	2014-01-30	Proteins that bind fc receptors
IL221371A0 (en)	2012-10-31	Anti-lrp6 antibodies
PT2603528T (pt)	2016-12-01	Anticorpos glicosilados em fab
ZA201302459B (en)	2014-01-29	Antibodies
HK1186740A (en)	2014-03-21	Novel antigen binding proteins